Physician profile
Fredd E Miller
NPI 1346263175
$4,932.44
in general payments reported to CMS, 2019-2025
27 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $636 · 2021: $1,657 · 2022: $72.38 · 2023: $458 · 2024: $759 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,679.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,390.41 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Novo Nordisk INC | $499.73 | 2019-2025 | Wegovy |
| Amgen INC. | $412.39 | 2019-2025 | Evenity, Repatha, Prolia |
| Allergan, INC. | $265.86 | 2019-2020 | |
| Lilly USA, LLC | $265.86 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $166.47 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $145.34 | 2019-2020 | |
| Astellas Pharma US INC | $122.92 | 2019-2021 | |
| Amarin Pharma, INC. | $68.33 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $55.80 | 2019-2020 | |
| Medtronic, INC. | $52.45 | 2024 | Interstim |
| Pfizer INC. | $45.84 | 2020-2023 | |
| Astrazeneca Pharmaceuticals Lp | $25.31 | 2019-2024 | Farxiga |
| Sanofi Pasteur INC. | $24.78 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.34 | 2025 | Xifaxan |
| Inspire Medical Systems, INC. | $18.79 | 2025 | Inspire |
| Abiomed | $18.76 | 2025 | |
| Exact Sciences Corporation | $17.85 | 2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $16.91 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $16.68 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.97 | 2020 | |
| Currax Pharmaceuticals LLC | $14.60 | 2020 | |
| Genzyme Corporation | $13.64 | 2022 | |
| Glaxosmithkline, LLC. | $13.01 | 2023 | Arexvy, Shingrix, Boostrix |
| Regeneron Healthcare Solutions, INC. | $12.72 | 2019 | |
| Esperion Therapeutics, INC. | $11.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredd Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.